Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Volatility & Risk
Connect Biopharma has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Valuation & Earnings
This table compares Connect Biopharma and Dianthus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 951.16 | -$55.48 million | ($1.19) | -0.76 |
| Dianthus Therapeutics | $2.04 million | 1,936.54 | -$162.34 million | ($4.15) | -17.37 |
Connect Biopharma has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Connect Biopharma and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations for Connect Biopharma and Dianthus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Dianthus Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
Connect Biopharma presently has a consensus target price of $5.88, suggesting a potential upside of 548.24%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 80.10%. Given Connect Biopharma’s higher probable upside, equities research analysts plainly believe Connect Biopharma is more favorable than Dianthus Therapeutics.
Summary
Dianthus Therapeutics beats Connect Biopharma on 8 of the 15 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
